Nyxoah S.A. (NASDAQ:NYXH) Q3 2022 Results Earnings Conference Call November 8, 2022 4:30 PM ET
Company Participants
Jeremy Feffer - Vice President, Investor Relations
Olivier Taelman - Chief Executive Officer
Loïc Moreau - Chief Financial Officer
Conference Call Participants
Simran Kaur - Piper Sandler
Jonathan Block - Stifel Nicolaus
Ross Osborn - Cantor Fitzgerald
Operator
Good day. And thank you for standing by. Welcome to the Nyxoah Third Quarter 2022 Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
I would like to hand the conference call to your speaker today, Jeremy Feffer, Vice President, Investor Relations. Please go ahead.
Jeremy Feffer
Thank you, Michelle. Good afternoon and good evening, everyone, and welcome to our earnings call for the third quarter of 2022. Participating from the company today will be Olivier Taelman, Chief Executive Officer, and Loïc Moreau, Chief Financial Officer.
During the call, we will discuss our operating activities and review our third quarter financial results released after US markets closed today, after which we'll host a question-and-answer session. The press release can be found on the Investor Relations section of our website, and this call is being recorded and will be archived in the Events section of our Investor Relations website.
Before we begin, I would like to remind you that any statements that relate to expectations or predictions of future events, market trends, results or performance are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements.
Our forward-looking statements are based upon currently available information, and the company assumes no obligation to update these statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our Form 20-F filed with the Securities and Exchange Commission on March 24, 2022.
With that, I would like to turn the call over to Olivier.
Olivier Taelman
Thank you, Jeremy. Good afternoon. And good evening, everyone. And thank you for joining us for our third quarter of 2022 earnings call.
As an overview of the third quarter, I'm happy to report that we are on the verge of closing implants in our US pivotal study, DREAM. And we remain on track to have 12-month clinical data in fall 2023.